Jan Peter Mattsson
Fondateur chez ALBIREO PHARMA, INC.
Postes actifs de Jan Peter Mattsson
Sociétés | Poste | Début | Fin |
---|---|---|---|
ALBIREO PHARMA, INC. | Fondateur | 08/12/2003 | - |
Directeur Technique/Scientifique/R&D | 08/12/2003 | - | |
Directeur des opérations | 08/12/2003 | - | |
TOLERANZIA AB | Directeur/Membre du Conseil | 01/01/2020 | - |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Fondateur | 01/02/2008 | - |
Directeur des opérations | 01/02/2008 | - | |
Directeur/Membre du Conseil | 01/05/2008 | 01/02/2010 | |
Corporate Officer/Principal | 01/02/2008 | 01/05/2008 | |
Elobix AB
Elobix AB Miscellaneous Commercial ServicesCommercial Services Part of Ipsen SA, Elobix AB is a Swedish company that provides commercial physical research services. The company is based in Gothenburg, Sweden. | Directeur/Membre du Conseil | 01/11/2013 | - |
Historique de carrière de Jan Peter Mattsson
Anciens postes connus de Jan Peter Mattsson
Sociétés | Poste | Début | Fin |
---|---|---|---|
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 01/02/2008 | 01/07/2015 |
Directeur Général | 01/02/2008 | 01/07/2015 | |
Directeur des opérations | 01/02/2008 | 01/07/2015 | |
Fondateur | 01/02/2008 | 01/07/2015 | |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | - | - |
Formation de Jan Peter Mattsson
University of Gothenburg | Doctorate Degree |
Statistiques
Internationale
Suède | 6 |
Royaume-Uni | 2 |
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 4 |
Chief Operating Officer | 3 |
Founder | 3 |
Sectorielle
Health Technology | 5 |
Commercial Services | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
TOLERANZIA AB | Health Technology |
Entreprise privées | 5 |
---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Health Technology |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Health Technology |
Albireo Pharma, Inc.
Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
Elobix AB
Elobix AB Miscellaneous Commercial ServicesCommercial Services Part of Ipsen SA, Elobix AB is a Swedish company that provides commercial physical research services. The company is based in Gothenburg, Sweden. | Commercial Services |
- Bourse
- Insiders
- Jan Peter Mattsson
- Expérience